Sodium oxalate,99.5%

Sodium oxalate is an orally active dispersant and coordination agent. Sodium oxalate causes mitochondrial dysfunction. Sodium oxalate has catalytic enhancing activity. Sodium oxalate induces stable chronic kidney disease. Sodium oxalate induces highly malignant and undifferentiated breast tumors^{[1][2][3][4][5][6][7][8]}. In Vitro: Sodium oxalate (1-4 mM; 1-24 h) leads to time- and concentration-dependent decrease in cell survival, inhibits proliferation in LLCPK1, MDCK, renal fibroblast and endothelial cells^[2].
Sodium oxalate (0.1-2 mM; 24 h) causes mitochondrial dysfunction, reduces basal OCR and ATP-linked OCR in THP-1 cells^[3].
In Vivo: Sodium oxalate (Oxalic acid form; 810 μM; injected into mammary fatpad; every 3-4 days; 9 times, 29 days) induces highly malignant and undifferentiated breast tumors in female BALB/c or BALB/c nude mice^[4].
Sodium oxalate (Oxalic acid form; 0.5 mmol/kg; i.p.; once daily for 5 consecutive days) combined with DMSA reverses GaAs-induced oxidative stress, reducing arsenic and gallium levels in tissues of male Wistar albino rats^[6].
Sodium oxalate (50 μmol/g in calcium-free diet; p.o.) induces stable chronic kidney disease in C57BL/6 mice^[7].
Sodium oxalate (70 mg/kg body weight; p.o. in drinking water; 30 days) induces urolithiasis in male mice, increasing serum uric acid, creatinine, sodium, phosphate, oxalate levels and renal sodium, phosphate, oxalate deposition ^[8].